Gary Liska, with Alere Home Monitoring Inc, says Alere's commitment to patients' safety is why they supported the STABLE study.
Gary Liska, with Alere Home Monitoring Inc, says Alere’s commitment to patient safety is why they supported the STABLE study. They saw an opportunity with Medicare’s expansion of its coverage policy for self-testing, and decided to provide self-testing services to Medicare and practitioners.
Mr Liska also explains why the STABLE study results are so important.
“Within the last 3 years, there have been 5 clinical papers written on cost-effectiveness. The market remains very volatile right now, and clinicians, and particularly healthcare, is looking for the most cost-effective agent,” Mr Liska says. “The 5 studies that have been published are all consistent with a certain threshold of warfarin quality of between 65% and 73%, so those are thresholds that Alere looks at very carefully. It was really the impetus behind conducting this study.”
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More